Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04889625 · ClinicalTrials.gov registry record · NA

Evaluation of Investigational Daily Disposable Multifocal Contact Lenses Produced With Different Manufacturing Processes in Myopes

A NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.

Completed
Registry status
NA
Development phase
81
Enrollment target
6
Study locations

NCT04889625: Completed NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.

NCT04889625 is a NA study of Visual Acuity that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 81 participants, below the 136-participant average among 20 other Visual Acuity trials with a reported enrollment target (40% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04889625, a NA study of Visual Acuity, has completed, sponsored by Johnson & Johnson Vision Care.

COMPLETED
Registry status
NA
Development phase
81 participants
Enrollment target
6
Study locations

Study Summary

This is a single-masked, 2×3 crossover, randomized controlled, dispensing clinical trial to evaluate the visual performance (logMAR) and subjective vision responses of the Test Lens.

Primary Outcome

Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast (HLHC) lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be between 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181-208 cd/m2). For Interm

Conditions Studied

Interventions

  • DEVICE senofilcon A C3
  • DEVICE Dailies Total 1® Multifocal Contact Lenses

Study Locations (6)

Florida

  • Vue Optical Boutique - Jacksonville
  • St. Johns Eye Associates - Saint Augustine

Texas

  • Gulf Coast Vision Center - Houston
  • Tyler Eye Associates - Tyler

New York

  • Sacco Eye Group - Vestal

Ohio

  • Procare Vision Centers - Granville

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2021-05-21
Est. Completion 2021-07-21
Phase NA
Johnson & Johnson Vision Care

142 total trials

What the finished NCT04889625 record still lists

NCT04889625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 136-participant average among 20 other Visual Acuity trials with a reported enrollment target (40% lower).

The record links to 1 condition, with Visual Acuity appearing as the primary indexed condition, and to 2 interventions - of which senofilcon A C3 is the first listed.

NCT04889625 lists 6 locations in 4 states (Florida, Texas, New York).

Frequently Asked Questions

What is clinical trial NCT04889625 about?

NCT04889625 is a clinical study titled "Evaluation of Investigational Daily Disposable Multifocal Contact Lenses Produced With Different Manufacturing Processes in Myopes". This is a single-masked, 2×3 crossover, randomized controlled, dispensing clinical trial to evaluate the visual performance (logMAR) and subjective vision responses of the Test Lens.

What is the current status of trial NCT04889625?

This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2021-05-21. Estimated completion is 2021-07-21.

What conditions does trial NCT04889625 study?

This clinical trial studies the following conditions: Visual Acuity.

What interventions are being tested in trial NCT04889625?

The interventions under investigation include: senofilcon A C3 (DEVICE), Dailies Total 1® Multifocal Contact Lenses (DEVICE).

Who is sponsoring clinical trial NCT04889625?

This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04889625 being conducted?

This trial has 6 study locations across Florida, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Visual Acuity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04889625's enrollment target sits among peer trials

81 12th of 20 higher than 9 of 20 other Visual Acuity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Visual Acuity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04966481 · 81 participants · Phase 3

    Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

  • NCT05109429 · 81 participants · NA

    Developing a Clinical Outcome Assessment for Opioid Craving

  • NCT05112601 · 81 participants · Phase 2

    Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • NCT05305911 · 81 participants · Phase 2

    Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04889625, the US trial registry maintained by the National Library of Medicine. NCT04889625 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.